Comparative Pharmacology
Head-to-head clinical analysis: BAL versus PENTETATE ZINC TRISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAL versus PENTETATE ZINC TRISODIUM.
BAL vs PENTETATE ZINC TRISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Pentetic acid (diethylenetriaminepentaacetic acid, DTPA) forms stable chelates with metal ions, particularly radioactive transuranic elements such as plutonium, americium, and curium. The zinc trisodium salt exchanges zinc for the radioactive metal, forming a stable, soluble complex that is rapidly excreted via the kidneys, thereby reducing radiation exposure.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
1 g intravenous infusion over 1-2 hours once daily for up to 5 days.
None Documented
None Documented
Clinical Note
moderateBalsalazide + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Acetyldigitoxin
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Ouabain
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
The terminal elimination half-life is approximately 1.5 to 2 hours for the Zn-DTPA complex in patients with normal renal function. In the setting of acute radiation exposure, this rapid clearance allows for early chelation.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Primarily renal elimination of the chelated complex (e.g., Zn-DTPA). In adults, >95% of the administered dose is excreted unchanged in urine within 24 hours, with minor biliary/fecal excretion (<5%).
Category C
Category C
Chelating Agent
Chelating Agent
"The serum concentration of Ouabain can be decreased when it is combined with Balsalazide."